FDA Submission for Finerenone by Macleods Pharmaceuticals
Macleods Pharmaceuticals has submitted an ANDA for Finerenone, currently under review.
Published: July 16, 2026
Updated: July 16, 2026
Author: Humanexa Intelligence
Therapeutic area: Cardiology / Mineralocorticoid Receptor Antagonist
Company: Macleods Pharmaceuticals
Asset: Finerenone
Technology / Platform: mineralocorticoid receptor antagonists market
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Macleods Pharmaceuticals
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The submission of an ANDA for Finerenone by Macleods Pharmaceuticals signifies a potential shift in the competitive landscape of mineralocorticoid receptor antagonists. This could impact pricing strategies and market dynamics for existing players in this therapeutic area.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the review status and any subsequent approvals or market entry timelines for Finerenone.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.